
Fabry Disease Sangamo Reports Updated Phase 1/2 STAAR Data for Fabry Disease
Sangamo Reports Updated Phase 1/2 STAAR Data for Fabry Disease Fabry Disease Sangamo Therapeutics a genomic medicine company, has announced updated results from the Phase 1/2 STAAR study evaluating isaralgagene…

Antibodies.com & Cactus Partner to Speed Up Life Science Publishing
Antibodies.com and Cactus Communications Partner to Accelerate Life Science Manuscript Publication Antibodies.com, a leading provider of high-quality biological reagents for life science researchers, has announced a strategic partnership with Cactus…

Broken String Biosciences Unveils Catalyst Program to Accelerate Gene Editing Therapy Development
Broken String Biosciences Unveils Catalyst Program to Accelerate Gene Editing Therapy Development Broken String Biosciences a leader in advancing gene editing safety, has officially launched its Catalyst Early Access Program…

DLBCL Treatment Merck Begins Phase 3 Trial of Zilovertamab Vedotin
Merck Begins Phase 3 Trial of Zilovertamab Vedotin for DLBCL Treatment DLBCL Treatment Merck known as MSD outside the United States and Canada, has officially announced the initiation of waveLINE-010,…

Know Labs Technology Licensing (KTL) Announces Official Client Partnership
Know Labs Technology Licensing (KTL) Announces Official Client Partnership Know Labs is pleased to announce the official launch of its structured client engagement process for Know Labs Technology Licensing (KTL),…

GoodRx Names Christopher A. McGinnis as CFO
GoodRx the leading prescription savings platform in the United States, has announced the appointment of Christopher A. McGinnis as its new Chief Financial Officer (CFO), effective February 4, 2025. McGinnis,…

Onc.AI Secures FDA Breakthrough Device Designation for AI-Powered CT Response Model
Onc.AI Secures FDA Breakthrough Device Designation for AI-Powered CT Response Model Onc.AI, FDA a pioneering digital health company specializing in AI-driven oncology clinical management solutions, has achieved a significant milestone…

Pharmascience Signet, Athyrium, Hildred Successfully Exit Pharmaceutics International
Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital, and Pharmascience Announce Exit from Pharmaceutics International, Inc. A consortium of investors, including Pharmascience Signet Healthcare Partners, Athyrium Capital Management, Hildred Capital,…

Clinical Applications Expert Hong Jiang, MD, PhD, Excels in Translating Scientific Discoveries
Dr. Hong Jiang: Advancing Immunology from Scientific Breakthroughs to Clinical Applications Dr. Hong Jiang, MD, PhD, has been recognized in Marquis Who’s Who for her outstanding contributions to immunology and…

Clinical Research Leader Claxton Copeland III Honored by Marquis Who’s Who
Claxton Copeland III Recognized for Excellence in Clinical Research Claxton Copeland III has been selected for inclusion in Marquis Who’s Who, a prestigious recognition that highlights individuals based on their…

Marquis Who’s Who Honors Cheryl Custard for R&D Expertise
Marquis Cheryl Custard: A Pillar of Excellence in Research and Development Cheryl Custard has earned a prestigious spot in Marquis Who’s Who , a recognition reserved for individuals who demonstrate…

Phase 1 Data Prolong Pharmaceuticals to Present Preliminary PP-007 Findings for AIS at 2025 ISC
Prolong Pharmaceuticals to Present Preliminary Phase 1 Data for PP-007 in AIS at 2025 ISC Phase 1 Data Prolong Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company, is poised to make a…